TY - JOUR
T1 - Primary small cell neuroendocrine carcinoma of urinary bladder
T2 - An uncommon entity to be recognized
AU - Nabi, G.
AU - Singh, I.
AU - Ansari, M. S.
AU - Sharma, M. C.
AU - Dogra, P. N.
PY - 2001
Y1 - 2001
N2 - Introduction: To describe the clinical presentation, diagnosis and treatment outcome of neuroendocrine carcinoma of urinary bladder. Methods: Clinical and pathological findings of 11 patients with diagnosis of small cell neuroendocrine tumour (SCNE) of urinary bladder are reviewed between Jan. 1991 to Jan 2001. Clinical data including age, sex, presenting symptoms, clinical stage at presentation, modality of treatment and outcome were determined. Sections of the tumour were studied by immunohistochemical methods using various antibodies to determine neuroendocrine pattern. Results: Patient age ranged from 35 to 79 years (mean 60 years). The clinical presentation included, gross hematuria 6, increased urinary frequency and dysuria 3, hydroureteronephrosis with flank pain 2. 3 patients had open exploration for presumed bladder stones by suprapubic route. Undifferentiated carcinoma was the initial report in 2 and associated transitional cell carcinoma in 2 cases. Urinary cytology obtained in 4 patients showed poorly differentiated carcinoma. Immunohistochemistry showed in all cases. 7 patients had radical cystoprostatectomy with adjuvant chemotherapy and 4 patients had combination of chemotherapy and radiotherapy. The survival ranged from 6 months to 30 months (mean 16.5 months). Conclusion: Primary small cell neuroendocrine carcinoma of urinary bladder is an aggressive malignancy with poor long-term outcome. Awareness of clinical presentation with free application of immunocytochemistry is emphasized to diagnose this unusual malignancy at earliest.
AB - Introduction: To describe the clinical presentation, diagnosis and treatment outcome of neuroendocrine carcinoma of urinary bladder. Methods: Clinical and pathological findings of 11 patients with diagnosis of small cell neuroendocrine tumour (SCNE) of urinary bladder are reviewed between Jan. 1991 to Jan 2001. Clinical data including age, sex, presenting symptoms, clinical stage at presentation, modality of treatment and outcome were determined. Sections of the tumour were studied by immunohistochemical methods using various antibodies to determine neuroendocrine pattern. Results: Patient age ranged from 35 to 79 years (mean 60 years). The clinical presentation included, gross hematuria 6, increased urinary frequency and dysuria 3, hydroureteronephrosis with flank pain 2. 3 patients had open exploration for presumed bladder stones by suprapubic route. Undifferentiated carcinoma was the initial report in 2 and associated transitional cell carcinoma in 2 cases. Urinary cytology obtained in 4 patients showed poorly differentiated carcinoma. Immunohistochemistry showed in all cases. 7 patients had radical cystoprostatectomy with adjuvant chemotherapy and 4 patients had combination of chemotherapy and radiotherapy. The survival ranged from 6 months to 30 months (mean 16.5 months). Conclusion: Primary small cell neuroendocrine carcinoma of urinary bladder is an aggressive malignancy with poor long-term outcome. Awareness of clinical presentation with free application of immunocytochemistry is emphasized to diagnose this unusual malignancy at earliest.
KW - Carcinoma
KW - Neuroendocrine tumors
KW - Small cell cancer
UR - http://www.scopus.com/inward/record.url?scp=0035779911&partnerID=8YFLogxK
U2 - 10.1023/A:1020510130301
DO - 10.1023/A:1020510130301
M3 - Article
C2 - 12452617
AN - SCOPUS:0035779911
SN - 0301-1623
VL - 33
SP - 637
EP - 640
JO - International Urology and Nephrology
JF - International Urology and Nephrology
IS - 4
ER -